Managing Irritable Bowel Syndrome: A Comparative Guide to Treatment

Irritable bowel syndrome (IBS) is a chronic digestive condition that causes recurring abdominal pain along with changes in bowel habits, including diarrhea, constipation, or both. It affects millions of adults in the United States, making it one of the most common functional gastrointestinal disorders. Managing IBS effectively requires understanding the available treatment options, how they differ, and which is prescribed for each subtype of the condition.

April is Irritable Bowel Syndrome Month. In this article, we turn the focus to the available treatments that healthcare providers are able to prescribe to help ease a patient’s discomfort, since there are as yet no known cures for IBS. This article provides a detailed comparative overview of the key medications used in IBS treatment today.

What is IBS, and why does subtype matter?

IBS is not a single condition. It exists in distinct subtypes, each with its own pattern and treatment focus. It is one of the main sub-groups in what are known as functional gastrointestinal (GI) and motility disorders. Estimates may vary, but about 80-90 million in the U.S. have some form of these disorders.

Understanding which subtype applies is essential to comparing medications fairly.

• IBS-D (diarrhea-predominant): the dominant symptom is loose, frequent stools and urgency.
• IBS-C (constipation-predominant): the dominant symptom is infrequent, hard stools with straining and bloating.
• IBS-M (mixed): alternating episodes of diarrhea and constipation.
• IBS-U (undefined): symptoms vary and do not fit a clear pattern.

The distinction matters because most prescription medications target one subtype specifically. A drug approved for IBS-D is generally not appropriate for IBS-C, and vice versa. Diagnosis is based on symptom history rather than laboratory tests. There is no single diagnostic test for IBS. IBS is also distinct from inflammatory bowel disease (IBD) and conditions such as Crohn’s disease, with which it is sometimes confused. All treatment decisions should be made with a qualified healthcare provider.

How IBS medications work: the main drug classes

The medications used in managing IBS belong to several distinct classes, each acting on the gut through a different mechanism. Comparing them requires understanding how they work, not just what they treat.

Antibiotics: targeting gut bacteria

Xifaxan (rifaximin) is the only FDA-approved antibiotic for IBS-D. Unlike standard antibiotics, it works almost entirely within the gastrointestinal tract and is minimally absorbed into the bloodstream. Its mechanism is not fully understood, but it appears to modify gut bacterial activity, reduce bacterial byproducts, and may have anti-inflammatory effects. It is usually taken three times daily for 14 days. Symptom relief can persist for up to 10 weeks after the course ends, and a second course is permitted if symptoms return. The most common side effect is nausea. Because rifaximin is not systemically absorbed, it carries a low risk of systemic drug interactions and is generally well tolerated.

Secretagogues: increasing fluid secretion

This class stimulates the bowel to secrete more fluid, improving stool consistency and easing constipation. It is used exclusively in IBS-C.

• Linzess (linaclotide) activates guanylate cyclase receptors in the intestinal lining, increasing fluid and electrolyte secretion into the bowel. It also appears to reduce abdominal pain. Two phase III trials demonstrated significant improvement in both abdominal pain and bowel movement frequency. The most common side effect is diarrhea.
• Trulance (plecanatide) works through the same receptor type as linaclotide and has a similar efficacy and safety profile. Diarrhea is also the most frequently reported side effect. Both drugs act locally and are minimally absorbed, reducing the risk of systemic effects.

Retainagogues: blocking sodium absorption

Ibsrela (tenapanor) is the first and currently only drug in this class approved for IBS-C. It blocks a sodium transporter (NHE3) in the intestinal lining, which reduces sodium absorption from food. This draws water into the intestinal lumen, softening stools and speeding transit. Tenapanor received FDA approval in 2019 and became commercially available in 2022. It has also been shown to reduce abdominal pain. Common side effects include diarrhea, abdominal distension, and flatulence. It is minimally absorbed and acts locally in the gut.

Antispasmodics and anticholinergics: reducing intestinal spasm

These drugs work by suppressing smooth muscle contractions in the gut wall, which can reduce cramping and abdominal pain. They are used across IBS subtypes, often for symptom relief rather than subtype-specific management.

• Buscopan (hyoscine butylbromide) is an anticholinergic antispasmodic that reduces intestinal cramping. It can be taken daily or as needed, and each dose is typically taken 30–60 minutes before meals.
• Antispasmodics as a class carry a conditional recommendation from the American Gastroenterological Association (AGA) for global IBS symptom relief.

Antidiarrheals: slowing intestinal transit

Imodium/Stop It (loperamide) slows the movement of contents through the bowel, reducing stool frequency and urgency. It is used in IBS-D for symptom control and carries a conditional recommendation from the AGA. It does not address abdominal pain and is not a disease-modifying treatment, but it can provide practical daily relief for patients with diarrhea-predominant symptoms.

Prokinetics: supporting gut motility

Motilium (domperidone) acts on the upper gastrointestinal tract, supporting gastric emptying and reducing symptoms such as nausea and bloating. It is not an IBS-specific treatment but may be used in some patients where upper GI motility is a contributing factor to overall symptom burden.

Comparing IBS medications: a treatment overview

What clinical guidelines say about managing IBS

The American Gastroenterological Association (AGA) issued updated guidelines on IBS pharmacotherapy in 2022. The guidelines give a strong recommendation for Linzess (linaclotide) in IBS-C and conditional recommendations for Ibsrela, Trulance, Xifaxan (including retreatment), Imodium/Stop It, antispasmodics, and tricyclic antidepressants in their respective indications. These recommendations reflect the evidence base across randomized controlled trials and should be read in the context of individual patient assessment. A prescribing physician is the appropriate guide to determine which option is right for any specific patient.

Sourcing IBS medications through IsraelPharm

For patients prescribed branded IBS medications in the United States, sourcing can present practical challenges. Several of the medications covered in this article , including Xifaxan, Linzess, Trulance, and Ibsrela, carry significantly higher retail price tags in the US market. IsraelPharm is a licensed international pharmacy operating under regulatory oversight, and it supplies the exact branded medications prescribed, not substitutes or generics unless the prescription specifically calls for them.

For patients managing a chronic condition like IBS, treatment reliability matters. IsraelPharm supports supply continuity for ongoing treatment, removing the risk of local stock gaps or delays between prescriptions. Medications are delivered directly to the patient’s home, making repeat supply practical for those on longer-term treatment plans. A valid prescription from a licensed physician is required, and the patient’s physician’s oversight of the treatment plan is not affected by using an international pharmacy for supply.

How to access treatment of IBS through IsraelPharm

Patients sourcing IBS medications such as Xifaxan, Linzess, Trulance, Ibsrela, Buscopan, or Imodium through IsraelPharm benefit from three specific advantages. First, the cost of these branded medications through IsraelPharm is significantly lower than US retail pricing – a meaningful consideration for patients who require ongoing or repeat treatment for a chronic condition like IBS. Second, IsraelPharm stocks the exact branded product prescribed, ensuring the patient receives the specific formulation their physician has recommended. Third, delivery directly to the patient’s home means no repeat pharmacy visits and straightforward reordering for continuing supply.

IsraelPharm is a licensed international pharmacy. A valid prescription from a licensed physician is required for all prescription medications listed here. Visiting the IsraelPharm website allows patients to confirm product availability, review pricing, and begin the process of sourcing their prescribed medication.

Frequently asked questions about managing IBS

What is IBS, and how is it different from inflammatory bowel disease?

IBS is a functional gastrointestinal disorder. It causes real symptoms but without visible structural damage to the gut. Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves measurable inflammation and physical changes to the bowel wall. IBS does not increase the risk of IBD, colon cancer, or serious gut disease. The two conditions are diagnosed and managed differently. A gastroenterologist can distinguish between them through symptom history and appropriate testing.

How does managing IBS with Xifaxan differ from using antispasmodics like Buscopan?

Xifaxan and Buscopan target different aspects of IBS. Xifaxan targets gut bacteria to address global IBS-D symptoms, including bloating, abdominal pain, and stool consistency, over a defined 14-day course. Buscopan targets smooth muscle spasms to reduce cramping and pain. The two approaches are not interchangeable:

• Xifaxan is indicated specifically for IBS-D.
• Buscopan can be used across IBS subtypes for pain relief.
• Neither replaces the other in clinical practice.

What are the differences between Linzess, Trulance, and Ibsrela for managing IBS with constipation?

All three are approved for IBS-C and act locally in the gut with minimal systemic absorption. Their key differences are in mechanism:

• Linzess and Trulance are both guanylate cyclase agonists. They increase fluid secretion into the bowel to soften stools and relieve pain.
• Ibsrela works differently. It blocks sodium absorption in the intestinal lining, retaining water in the bowel to ease constipation.
• Diarrhea is the most common side effect of all three. Choice between them is typically guided by individual patient response and physician preference.

Can IBS medications be used long-term, and what does that mean for supply?

Most IBS-C medications, including Linzess, Trulance, and Ibsrela, are intended for ongoing use as long as they remain effective and tolerated. Xifaxan differs: it is taken as a 14-day course, with a second course permitted if symptoms recur. For patients on long-term daily dosing, supply continuity is an important practical consideration. Gaps in supply can disrupt treatment. IsraelPharm supports ongoing supply for patients on continuing IBS therapy, with home delivery and straightforward repeat ordering.

How does managing IBS with loperamide compare to prescription IBS-D treatments?

Loperamide (Imodium/Stop It) slows gut transit and reduces stool frequency. It is an AGA-recommended option for IBS-D and is widely accessible. However, it does not address abdominal pain, bloating, or the underlying gut dysfunction associated with IBS-D. Prescription options like Xifaxan are considered global treatments; they address multiple IBS-D symptoms simultaneously. The right choice depends on symptom severity, treatment history, and physician guidance. Loperamide may be appropriate for mild or intermittent symptoms; prescription therapy is typically considered where symptoms are more disruptive.

Further reading on managing IBS

From our website

• Managing IBS with prescription medications — Blog
• Xifaxan (rifaximin) for IBS-D — Blog

From the World Wide Web

• Medications for IBS — About IBS (IFFGD)
• What is IBS? — About IBS (IFFGD)
• AGA pharmacological management of IBS — American Gastroenterological Association

Glossary

• Anticholinergic: A drug that blocks acetylcholine at nerve-muscle junctions, reducing intestinal smooth muscle contractions and cramping.
• Antispasmodic: A medication that suppresses involuntary muscle spasms in the gastrointestinal tract, relieving pain and cramping.
• Functional gastrointestinal disorder: A condition involving real GI symptoms without detectable structural or inflammatory disease in the gut.
• Guanylate cyclase agonist: A compound that activates guanylate cyclase receptors in the intestinal lining, increasing fluid secretion and bowel movement frequency.
• Gut microbiota: The community of bacteria and other microorganisms living in the gastrointestinal tract, which influences digestion and immune function.
• IBS-C: The constipation-predominant subtype of irritable bowel syndrome, characterized by infrequent, hard stools and abdominal discomfort.
• IBS-D: The diarrhea-predominant subtype of irritable bowel syndrome, characterized by frequent loose stools, urgency, and abdominal pain.
• Inflammatory bowel disease (IBD): A group of conditions, including Crohn’s disease and ulcerative colitis, involving chronic inflammation and structural damage to the gut wall.
• NHE3 inhibitor: A drug that blocks the sodium-hydrogen exchanger 3 transporter in the intestine, reducing sodium absorption and retaining water in the bowel.
• Prokinetic: A drug that accelerates the movement of contents through the gastrointestinal tract by stimulating coordinated muscle contractions.
• Retainagogue: A class of drug that retains water in the intestinal lumen by reducing sodium absorption, softening stools and speeding transit.
• Secretagogue: A drug that stimulates increased fluid and electrolyte secretion into the intestinal lumen, improving stool consistency in constipation.
• SIBO (small intestinal bacterial overgrowth): An abnormal increase in bacteria in the small intestine, associated with bloating, gas, and altered bowel habits in some IBS patients.